Abstract
Fundamental and clinical studies on a new carbapenem antibiotic, imipenem/cilastatin sodium (MK-0787/MK-0791), were carried out in the field of obstetrics and gynecology. The following results were obtained.
1. The concentration of MK-0787 in uterine tissue was 3.5-8.2 μg/g at about 30 minutes after an administration of 0.5g/0.5g of MK-0787/MK-0791 by a 30-minute intravenous drip infusion. The concentration decreased to less than 0.5 μg/g by approximately 3 hours.
2. The level of MK-0787 in the pelvic dead space exudate reached a peak of 24.0±4.4 μg/ml at 1 hour after an administration of MK-0787/MK-0791 0.5g/0.5g and was higher than the plasma level at 1 hour. The level in the pelvic dead space exudate was 2.0±0.8 μg/ml at about 6 hours.
3. The MK-0787/MK-0791 was administered to 4 patients with gynecologic infections (2 patients with pelvic peritonitis, 1 patient with salpingitis, 1 patient with a vulvar abscess). The clinical efficacy was good in all 4 patients. Neither adverse effects nor abnormal laboratory findings were observed.
It appears that MK-0787/MK-0791 is a safe and useful antibiotic for the treatment of obstetrical and gynecological infections.
